For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

"At Castle Biosciences, our commitment to advancing care for melanoma patients helps drive our continuous innovation," said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, ...

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

Prostate cancer is the second-leading cause of cancer deaths among men in the United States and the rate of men diagnosed with advanced disease has been growing in recent years. 1 Veracyte estimates ...

Researchers from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) have applied AI-driven processes for detecting tertiary ...

Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology company, emphasizing the regulatory and commercial advancements. He announced ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

Incorporating the 40-GEP test with BWH staging and NCCN risk group significantly improved risk stratification.

Cancer apps can provide patients with helpful tools, but there are risks associated with these apps, according to experts.

Health insurance companies make decisions on treatment but they aren't medical professionals. HB 434 would put decisions in ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...